Hudson Bay Capital Management LP Grows Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Hudson Bay Capital Management LP grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 362.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,134 shares of the company’s stock after buying an additional 18,134 shares during the period. Hudson Bay Capital Management LP’s holdings in Kymera Therapeutics were worth $1,309,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Federated Hermes Inc. purchased a new position in Kymera Therapeutics in the third quarter worth $31,622,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after purchasing an additional 10,052 shares during the last quarter. Candriam S.C.A. boosted its position in shares of Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock worth $10,847,000 after purchasing an additional 37,536 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in Kymera Therapeutics by 272.7% in the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after acquiring an additional 359,847 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Kymera Therapeutics by 26.3% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after purchasing an additional 22,392 shares in the last quarter.

Insider Activity

In other news, insider Jared Gollob sold 4,895 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total value of $417,543.50. Following the completion of the sale, the insider directly owned 117,134 shares in the company, valued at $9,991,530.20. This represents a 4.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jeremy G. Chadwick sold 25,758 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the completion of the transaction, the chief operating officer directly owned 68,052 shares in the company, valued at $5,668,731.60. This trade represents a 27.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 196,561 shares of company stock valued at $17,097,428 in the last three months. Company insiders own 16.01% of the company’s stock.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several research analyst reports. Bank of America boosted their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Oppenheimer boosted their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Morgan Stanley restated an “overweight” rating and issued a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. HC Wainwright lifted their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Piper Sandler boosted their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.90.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $77.91 on Monday. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The company has a market cap of $6.36 billion, a price-to-earnings ratio of -21.17 and a beta of 2.20. The stock has a 50 day simple moving average of $79.71 and a 200-day simple moving average of $69.84.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same quarter last year, the business earned ($0.88) EPS. The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. Analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.